NOYES TIMOTHY P 4
4 · Aerovate Therapeutics, Inc. · Filed May 17, 2024
Insider Transaction Report
Form 4
NOYES TIMOTHY P
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-05-16−10,000→ 343,381 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2024-05-16$2.14/sh+10,000$21,400→ 10,000 total - Sale
Common Stock
2024-05-16$21.52/sh−8,707$187,410→ 1,293 total - Sale
Common Stock
2024-05-16$21.92/sh−1,293$28,345→ 0 total
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.87 to $21.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.87 to $22.035, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.